Indian pharmaceutical company selling branded formulations, with a focus on women's health and gastroenterology.
Indian pharmaceutical company selling branded formulations, with a focus on women's health and gastroenterology.
In one line: A domestic branded-generics maker.
Moat: narrow (brand). Doctor-relationship-driven branding in a few chronic therapy niches within India.
Headquarters: Ahmedabad, India · Employees: 5,153
Size Corona Remedies (CORONA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.48B, the 481st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,256 on 18 Nov 2026.
Performance Over six months the shares gained 26.6%, against -11.8% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 17.2% over the last twelve months (peer median +1.5%); the operating margin is 18.4% (peer median 11.0%).
Valuation It trades at 58.9× forward earnings against a peer median of 25.6× (most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 13.5 points above its cost of capital (12.6% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹15.6B | ₹14.0B | ₹12.0B | ₹10.1B | ₹8.84B |
| Revenue growth | — | +17% | +18% | +15% | — |
| Gross profit | ₹7.78B | ₹6.01B | ₹5.00B | ₹3.95B | ₹3.38B |
| EBITDA | ₹3.34B | ₹2.95B | ₹2.41B | ₹1.66B | ₹1.28B |
| Net income | ₹2.07B | ₹1.85B | ₹1.49B | ₹905M | ₹849M |
| Free cash flow | n/a | ₹572M | ₹954M | -₹1.37B | ₹111M |
| Capital expenditure | n/a | ₹1.74B | ₹916M | ₹2.86B | ₹948M |
| Total debt | ₹1.15B | ₹1.65B | ₹862M | ₹1.59B | ₹280M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Corona Remedies CORONA.NS | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% |
| Eris Lifesciences ERIS.NS | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% |
| Mankind Pharma MANKIND.NS | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CORONA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.2% | -4.6% | 2nd highest of 21 |
| 6-month return | +26.6% | -11.8% | 3rd highest of 21 |
| Distance from 52-week high | -17.0% | -40.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +17.2% | +1.5% | 6th highest of 20 |
| Operating margin | 18.4% | 11.0% | 4th highest of 20 |
| Forward P/E | 58.9× | 25.6× | most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 36.3% | -6.1% | most demanding of 12 |
| Growth delivered (Del g) | +16.6% | +1.9% | 2nd highest of 12 |
| Hurdle (Req g minus delivered) | +19.7 pp | -5.1 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | +13.5 pp | -1.3 pp | 2nd highest of 21 |
| EV / EBITDA | 41.3× | 16.1× | most expensive of 6 |
| Net debt / EBITDA | 0.1× | 2.8× | 3rd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 27.2× | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.51B | -71% | -53% | -201% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.52B | -9% | +16% | 24% | n/a | -4.9% | +0.2% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.52B | -4% | +4% | 9% | 16.0× | -6.1% | +1.9% |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Sarepta Therapeutics SRPT | United States | $1.56B | -15% | -19% | 0% | n/a | -6.8% | +32.4% |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| Yifan Pharmaceutical 002019.SZ | China | $1.57B | -19% | -5% | 8% | 25.6× | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.59B | 0% | -4% | 15% | 47.2× | 6.0% | -4.3% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.59B | -8% | +18% | 7% | 29.0× | n/a | n/a |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.59B | -14% | -13% | 6% | 12.6× | -6.6% | -5.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.60B | -31% | -13% | 12% | 57.4× | 12.8% | -14.0% |
| Sino Biological 301047.SZ | China | $1.60B | +27% | +20% | 17% | 51.6× | 31.1% | -15.1% |
| Anupam Rasayan India ANURAS.NS | India | $1.61B | -3% | +24% | 16% | 49.9× | n/a | n/a |